1. •• Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults. JAMA. 2016;316:191. International guidelines produced by a recognized expert panel that updates first-line regimen based on the latest clinical evidence. the last evidence.
2. •• Gulick RM. Choosing initial antiretroviral therapy: current recommendations for initial therapy and newer or investigational agents. Top Antivir Med. 2015;23:128–31. Comprehensive review of factors taking into account when initiating ARV therapy.
3. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy. JAIDS. 2004;36:808–16.
4. Boyle B, Lackey P, Morales-Ramirez J. Early assessment of adherence and treatment satisfaction differences in a QD versus a BID or more frequently dosed HAART regimen. In: 11th International Congress on Infectious Diseases. Cancun, Mexico; 2004. Poster 12.026.
5. •• Derache A, Shin H-S, Balamane M, White E, Israelski D, Klausner JD, et al. HIV drug resistance mutations in proviral DNA from a community treatment program. PLoS One. 2015;10, e0117430. Study showing that DNA can be detected in a quarter of aviremic patients, and a good genotype concordance between DNA and RNA in viremic patients, which suggests DNA genotyping might be used for testing suppressed patients before switching.